Acanthosis nigricans
☆ AI Dermatology — Free Service
In anno 2022 Stiftung Warentest ex Germania provenit, satisfactio consumptoria cum ModelDerm paulo minus fuit quam cum consultationibus telemedicinis solutis.
In anno 2022 Stiftung Warentest ex Germania provenit, satisfactio consumptoria cum ModelDerm paulo minus fuit quam cum consultationibus telemedicinis solutis.
Communis in populo obeso.
relevance score : -100.0%
ReferencesAcanthosis nigricans est manifestatio cutanea conditionis subiectae. Saepe apparet in plicis cutis, ut in collo, axillis et inguina, velut maculae obscurae velutinae. Haec conditio plerumque cum diabete et resistentia insulinica coniungitur, sed raro potest indicare cancerem internum. Potest etiam apparere ob perturbationes hormonales vel propter usum medicamentorum specificorum, ut steroides et pilulas contraceptivas.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans (AN) est condicio cutis communis, variis exitibus sanitatis coniuncta, sicut resistentia insulinica, diabetes, morbus macrovascularis, quaedam carcinomata, problemata hormonalia et reactiones ad medicamenta. De AN loquimur in contextu quaestionum salutis subiectarum. Primum, medici examinant signa syndromatis resistentiae insulinicae, quae includunt ADIPS, hypercholesterolemiam, hypertensionem et diabetes typi 2. Medici saepe praecipiunt retinoides topicos ut primam curationis optionem, quae adiuvant in cute crassa. Sed haec optio non semper est completa. Aliae optiones curationis, ut salicylic acid, podophyllin, urea, calcipotriol, etiam requirunt frequentem applicationem.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
○ Causae
Plerumque in hominibus sub XL annis occurrit; potest esse hereditarium et coniungitur cum obesitate vel endocrinopathiis, ut hypothyroidismus, acromegalia, morbus ovarii polycystici, diabetes insulinore‑resistens vel morbus Cushingii.
○ Curatio OTC Medicamenta
#40% urea cream